Last updated on February 2019

Study of E7389 Liposomal Formulation in Subjects With Solid Tumor


Brief description of study

The maximum tolerated dose (MTD) of E7389 liposomal formulation (E7389-LF) will be determined in the dose escalation part. Safety, pharmacokinetics (PK) and efficacy will be assessed using treatment regimen evaluated in dose escalation part in participants with breast cancer in the expansion part 1 and adenoid cystic carcinoma (ACC) in the expansion part 2.

Clinical Study Identifier: NCT03207672

Contact Investigators or Research Sites near you

Start Over

Customer Joy Department. EJ

Eisai Trial Site 2
Osaka, Japan
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.